MAYZENT

USDailyMed:Siponimod AU:D L04AE03(WHO) AU:S4(Prescription only)CA:℞-onlyUK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) 1-({4-[(1E)-1-({[4-cyclohexyl- 3-(trifluoromethyl)phenyl]methoxy}imino)ethyl]-2-ethylphenyl}methyl)azetidine-3-carboxylic acid 1230487-00-9 44599207 DB12371 29315058 RR6P8L282I D11460as salt:D11072 ChEMBL2336071 DTXSID40153847 Interactive image CCc1cc(C(C)=NOCc2ccc(C3CCCCC3)c(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1 InChI=1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)/b33-19+Key:KIHYPELVXPAIDH-HNSNBQBZSA-N Siponimod, sold under the brand nameMayzent, is a selectivesphingosine-1-phosphatereceptormodulator for oral use that is used formultiple sclerosis(MS).It is intended for once-daily oral administration. In March 2019, it was approved in the United States to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.